JP MORGAN 2015: Roche in dealmaking mode for antibiotics, diagnostics
This article was originally published in Scrip
Roche told Scrip on 12 January during the 33rd Annual JP Morgan Healthcare Conference in San Francisco that the company is actively looking to do deals in oncology, neurology and infectious diseases and by the end of the day unveiled a new licensing deal for a Phase I antibiotic.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.